{"doi":"10.29011/2574-7258.010123","title":"Cationic Antimicrobial Peptides: Current Applications and Future Perspectives in Human Medicine","abstract":"Cationic Antimicrobial Peptides (CAPs) represent a promising class of therapeutics in the fight against multidrug-resistant infections, offering a novel mechanism of action distinct from traditional antibiotics.These peptides, which exhibit broadspectrum antimicrobial properties, are involved in immune modulation and tissue repair.CAPs, including defensins, cathelicidins, magainins, and synthetic analogs, have been studied extensively for their potential in treating a variety of infections, such as skin and soft tissue infections, pulmonary diseases, urinary tract infections, and medical device-associated infections.Despite strong preclinical data supporting their efficacy, clinical translation has faced challenges related to peptide stability, toxicity, and manufacturing costs.Ongoing clinical trials have yielded promising results, particularly for topical and localized applications, with peptides such as pexiganan, omiganan, and brilacidin showing encouraging outcomes in treating chronic wounds, catheterassociated infections, and oral mucositis.Moreover, recent advancements in drug delivery systems, such as inhalable formulations and nanoparticle encapsulation, are addressing issues of bioavailability and systemic delivery.However, systemic use remains a critical area of investigation due to concerns about peptide stability and potential adverse effects.This review explores the current state of CAP-based therapies, highlighting ongoing clinical trials, the challenges faced in their clinical integration, and their future perspectives in human medicine, particularly in addressing the growing threat of antimicrobial resistance.","journal":"Advances in Biochemistry and Biotechnology","year":2025,"id":587197,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9523,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1502841,"name":"Emmanuel Andres","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:59:36.020030Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}